Gene Study Shows Why Skin of Older People Scars Less

September 26, 2018
Gene Study Shows Why Skin of Older People Scars Less
Source: niphon/Getty Images

We all stand the risk of accumulating scars throughout our lifetimes, but curiously, in old age, the likelihood that a wound will leave a thick, ugly scar is much reduced. How older skin is advantaged has been unclear, even though dermatologists and plastic surgeons have consistently observed that older people’s wounds heal with thinner scars. A new study, however, has exposed the role of a blood-borne stromal factor in scarring. The study suggests that suppression of this factor, which is expressed by the SDF1 gene, could improve tissue regeneration.

The new findings emerged in experiments in mice and were confirmed in experiments with human tissue. Details of all this work appeared recently in the journal Cell Reports, in an article titled, “Aging Suppresses Skin-Derived Circulating SDF1 to Promote Full-Thickness Tissue Regeneration.”

The article describes how a team of scientists based at the University of Pennsylvania (UPenn) School of Medicine pierced the ears of mice of different ages—the equivalent of a 12-year-old and a 70-year-old if converted to human years. The hole closed with no scar formation in older mice, while younger mice healed with a visible scar. Researchers then exchanged the blood of young mice with old mice, pierced their ears, and found that the ears of old mice now scarred. They concluded whatever was causing the scarring must be something in the blood.

The team then took tissue samples from young and old mice and compared their gene expression signatures. They identified 80 differences, too many to study. But when they asked which gene products are found in the bloodstream, the list narrowed to 13 suspects. One was SDF1, a signaling molecule that was previously shown to play a role in scar formation in the skin, liver, and lung, and it seemed like a promising possibility. They confirmed that SDF1 was expressed in younger mice but not older. To prove that SDF1 may be the causal factor, they created a mouse that lacked SDF1 in the skin. When SDF1 function was inactivated, even young mice began to regenerate skin, behaving, in this sense, like older mice.

"This is a rare instance where aging actually improves the body's ability to heal rather than diminishing it," says Thomas H. Leung, M.D., Ph.D., an assistant professor of dermatology at UPenn. "When we're younger, we secrete more SDF1 into the bloodstream to form scars, but as we age, we lose this ability, which allows tissue to regenerate."

To prove it, researchers exchanged the blood between young SDF1-deficient mice and older mice. This time, neither mouse scarred. The team went one step further and grew human skin in the lab, then injured it with a scalpel. Human skin also exhibited an age-dependent expression of SDF1.

“Genetic deletion of SDF1 in young skin enhanced tissue regeneration,” the Cell Reports article detailed. “In aged mice, enhancer of zeste homolog 2 (EZH2) and histone H3 lysine 27 trimethylation are recruited to the SDF1 promoter at higher levels, and pharmacologic inhibition of EZH2 restores SDF1 induction and prevents tissue regeneration.”

SDF1, or stromal-derived-factor-1, has previously been shown to play a role in tissue regeneration of the skin, lung, and liver. Overexpression of SDF1, the UPenn team speculated, speeds up skin re-epithelialization: “From an evolution perspective, a young injured animal favors fast and imperfect wound repair over slow and perfect tissue regeneration. Future studies are needed to assess the relationship between skin re-epithelialization speed and scar formation.”

EZH2, the team found, modifies the DNA at the SDF1 gene and prevents the gene from being activated. "As the mice aged, we found more EZH2 at the SDF1 gene," Dr. Leung explains. By using a drug to block EZH2 function in elderly mice, the scientist saw that these mice regained SDF1 induction and lost their ability to regenerate their skin.

Dr. Leung notes that this work has the ability to impact the clinic relatively quickly. SDF1 inhibitors already exist on the market and currently used as a treatment to mobilize stem cells. He and his team plan to study its use in preventing scar formation in humans.